It was felt that Li-Fraumeni-like (LFL) criteria had largely been designed to broaden the clinical criteria and increase sensitivity for testing of TP53. Therefore, for LFL families without a TP53 PV, the lifetime risks of cancer were unlikely to be in the range of that observed for classic LFS and surveillance of this patient group was not supported. The gene discussed is TP53; the disease is cancer.